Maria-Polina Konstantinou, Caroline Dutriaux, Caroline Gaudy-Marqueste, Laurent Mortier, Christophe Bedane, Céline Girard, Sophie Thellier, Thomas Jouary, Jean-Jacques Grob, Marie-Aleth Richard, Caroline Templier, Lilia Sakji, Bernard Guillot, Carle Paul, Nicolas Meyer
DOI: 10.2340/00015555-1654

Treatment with ipilimumab, a monoclonal antibody that antagonizes cytotoxic T-lymphocyte antigen-4 (CTLA-4), results in improved survival of patients with stage IIIc–IV melanoma. However, there is a lack of data on the efficacy of ipilimumab in patients with brain metastases. To evaluate the efficacy of ipilimumab for the treatment of brain metastasis in melanoma, a multicentre, retrospective analysis of 38 patients with brain metastases in melanoma, treated with ipilimumab in the context of the French Expanded Access Program, was performed.
Three patients had a 3 partial response, 5 stable disease, 15 disease progression and 15 patients died during the induction phase due to disease progression. Median overall survival was 101 days (range 54–154). The brain metastases control rate was 16% (6/38). Ipilimumab may be effective in a few patients with central nervous system metastasis. However, patients with brain metastases and a low life expectancy may not benefit sufficiently from treatment with ipilimumab.

TableSI
TableSII